Health Technology Assessment

Health Technology Assessment (HTA) can be performed alongside the total translational research process. After phase III trials, HTA (e.g. a cost-effectiveness analysis) is used to apply for reimbursement. In earlier stages of the translational research process, “early HTA” can be used to anticipate on technological and environmental developments.

The vision of HTA in the NKI is to improve early detection, care and access (in terms of coverage and actual availability) of patients to cancer health services.
Our mission is to create evidence, using comprehensive assessments and innovative modeling techniques for informed decision making regarding new and existing (complex) technologies in oncology.

Our expertise

Cost-Effectiveness Analysis (CEA)

News and Highlights

Dissertation Nora Franzen

Affordable prices of innovative anticancer medicines are indispensable in enabling patients to receive the most suitable treatment. The prices of many pharmaceutical treatments are, presumably, leading to healthcare budgets approaching capacity limits globally, including in high-income countries. Anticancer treatments account for the largest cost category in specialized medical care. Strategies are needed to assure the affordability of medicines and sustainability of healthcare systems without compromising pharmaceutical innovation. This dissertation explores evidenced-based interventions that lead to affordable medicine prices in oncology at market launch in high-income European countries.